Dalbavancin: Difference between revisions
Elcatracho (talk | contribs) (→Common) |
Elcatracho (talk | contribs) |
||
| Line 19: | Line 19: | ||
===Renal Dosing=== | ===Renal Dosing=== | ||
* | *CrCl less than 30 mL/min and not receiving hemodialysis: Single-dose regimen, 1125 mg IV infusion; 2-dose regimen, 750 mg IV infusion followed by 375 mg IV infusion 1 week later<ref>Product Information: DALVANCE(R) intravenous injection, dalbavancin intravenous injection. Durata Therapeutics Inc. (per manufacturer), Parsippany, NJ, 2016.</ref> | ||
* | *No adjustment necessary if on [[hemodialysis]] | ||
===Hepatic Dosing=== | ===Hepatic Dosing=== | ||
Revision as of 06:24, 7 April 2021
Administration
- Type: Antibiotic
- Dosage Forms: 500 mg/vial; reconstituted concentration 20 mg/ml
- Routes of Administration: Intravenous
- Common Trade Names: Dalvance
Adult Dosing
- 1500 mg as single dose or 1000 mg then 500 mg one week later; infuse over 30 minutes
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
Special Populations
Pregnancy Rating
- Maternal risk cannot be ruled out
Lactation risk
- Fetal risk cannot be ruled out
Renal Dosing
- CrCl less than 30 mL/min and not receiving hemodialysis: Single-dose regimen, 1125 mg IV infusion; 2-dose regimen, 750 mg IV infusion followed by 375 mg IV infusion 1 week later[1]
- No adjustment necessary if on hemodialysis
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Gastrointestinal: Clostridium difficile colitis (<2%), Clostridium difficile diarrhea, GI bleed (<2% )
- Hepatic: ALT/SGPT level raised (0.8%)
- Immunologic: Hypersensitivity reaction
Common
- Gastrointestinal: Diarrhea (Up to 4.4%), Nausea (Up to 5.5%)
- Neurologic: Headache (Up to 4.7%)
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
Mechanism of Action
Comments
See Also
References
- ↑ Product Information: DALVANCE(R) intravenous injection, dalbavancin intravenous injection. Durata Therapeutics Inc. (per manufacturer), Parsippany, NJ, 2016.